Technology Bundle ID: TAB-2699

Nucleic Acid-based Differentiation and Identification of Medically Important Fungi

Request More Info
Licensing Contact:
Primary Inventors: 
Christine Morrison (CDC), Mark Lindsley (CDC)
Jong Soo Choi (CDC), Zhenyu Qin (CDC)
Development Stage: 
Pre-Clinical (in vitro)
Development Status: 

In vitro data available

Institute or Center: 

This invention, entailsnucleic acid-based assays, for detecting the presence of pathogenic fungi such as Histoplasma capsulatum, Blastomyces dermatitidis, Coccidioides immitis, Pneumocystis brasiliensis, and/or Penicillium marneffei within a sample. Within a healthcare setting, this particular approach can greatly reduce pathogen identification time, better direct treatments and ultimately improve patient outcomes. Further, this technology provides improved diagnostic specificity compared to serologic tests for circulating antibodies using patient serum samples- an approach that may give particularly aberrant results for immunosuppressed individuals, and who are frequently afflicted with opportunistic fungi. This technology is readily adaptable as kits used for species-specific identification of fungal pathogen infections and environmental contamination.

  • Directing antifungal drug therapy for improved patient outcomes
  • Detection, discrimination of fungal pathogens
  • Addressing secondary infections of immunosuppressed individuals or asthmatics
  • Rapid, sensitive, simple and specific
  • Potential for automation and high-throughput screening
  • Easily adaptable to kit form


PCT Application PCT/US2002/030605
Filed on 2002-09-25
US Application 60/325,241
Filed on 2001-09-26
US Pat 7,427,472

Issued 2008-09-23


Lindsley MD, et al.
PMID 11574564


Dec 23, 2013

Data Source: